Vertaling van "submitted applications " (Nederlands → Frans) :

TERMINOLOGIE

extracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur extracorporel de système d’hyperthermie de circulation extravasculaire

applicator voor aneurysmaclip
applicateur de clips d’anévrisme

applicator voor compressiekousen
enfile-bas de contention

applicator voor dermale anesthesie
applicateur dermique d’anesthésie locale

handbediende applicator voor brachytherapiesysteem voor oog
applicateur manuel de système de brachythérapie oculaire

applicator voor thermisch pulsatiesysteem voor ooglid
applicateur pour système de traitement thermique par impulsions sur les paupières

intracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur intracorporel de système d’hyperthermie de circulation extravasculaire

handbediende applicator voor oesofageaal brachytherapiesysteem
applicateur manuel de système de brachythérapie pour l’œsophage

applicator voor oesofageaal brachytherapiesysteem met op afstand bedienbare afterloading
applicateur de système de brachythérapie pour l’œsophage à chargement différé à distance

applicator voor tandheelkundige hars
applicateur de matériau de restauration dentaire

IN-CONTEXT TRANSLATIONS

Submitted applications Validated applications Applications in “Parking”system Finalised applications
Submitted applications Validated applications Applications in “Parking”system Finalised applications

Of the submitted applications, 95% were processed within the set time limits.
Of the submitted applications, 95% were processed within the set time limits.

Some achievements and figures for the Veterinary Medicines unit in 2007 KPIs and measurement results The most important KPI for this unit is the proportion of the number of finalised applications to the number of new, submitted applications, as a measure of the evolution of the unit’s backlog.
Some achievements and figures for the Veterinary Medicines unit in 2007 KPIs and measurement results The most important KPI for this unit is the proportion of the number of finalised applications to the number of new, submitted applications, as a measure of the evolution of the unit’s backlog.

Work is proceeding on adjusting the existing regulations in order to introduce administrative simplifications, such as the accelerated determination of the acceptability of submitted applications.
Work is proceeding on adjusting the existing regulations in order to introduce administrative simplifications, such as the accelerated determination of the acceptability of submitted applications.

It is also clear that the number of submitted applications continues to rise sharply compared with previous reference periods.
It is also clear that the number of submitted applications continues to rise sharply compared with previous reference periods.

For 2007, an analysis has been performed of the number of submitted applications versus the number of MA of medicines for human use granted.
For 2007, an analysis has been performed of the number of submitted applications versus the number of MA of medicines for human use granted.

Number of submitted applications - IN
Number of submitted applications - IN

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.